Sotorasib Is a Pan- <i>RAS</i> G12C Inhibitor Capable of Driving Clinical Response in <i>NRAS</i> G12C Cancers
Douglas A. Rubinson(Harvard University), Ryan B. Corcoran(Massachusetts General Hospital)
Cited by 40
Related Papers
Resistance to checkpoint blockade therapy through inactivation of antigen presentation
|Nature Communications|2017|999
Elevation of circulating branched-chain amino acids is an early event in human pancreatic adenocarcinoma development
|Nature Medicine|2014|664
Microenvironment drives cell state, plasticity, and drug response in pancreatic cancer
|Cell|2021|586
Liquid versus tissue biopsy for detecting acquired resistance and tumor heterogeneity in gastrointestinal cancers
|Nature Medicine|2019|521
ctDNA applications and integration in colorectal cancer: an NCI Colon and Rectal–Anal Task Forces whitepaper
|Nature Reviews Clinical Oncology|2020|365